What is Nyxoah (NYXH) stock price today?

Nyxoah (NYXH) currently trades at $2.95 per share. The stock has a market capitalization of $130.99M and a P/E ratio of —x.

Is NYXH stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Nyxoah has a Smart Value Score of 29/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 2/9 and Altman Z-Score is —.

What is Nyxoah's revenue and earnings?

Nyxoah has trailing twelve-month (TTM) revenue of $10.02M with profit margins of 0.00%. Earnings per share (EPS) is $-2.77.

Is Nyxoah financially healthy?

Nyxoah's Piotroski F-Score is 2/9 (weak financial health). The Altman Z-Score of — places it in the —.

NYXH

Nyxoah

NASDAQ: NYXH · HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES

$2.95

+0.68% today

Updated 2026-04-30

Market cap

$130.99M

P/E ratio

—

P/S ratio

13.07x

EPS (TTM)

$-2.77

Dividend yield

—

52W range

$3 – $9

Volume

0.1M

Market cap

$130.99M

P/E ratio

—

P/S ratio

13.07x

EPS (TTM)

$-2.77

Dividend yield

—

52W range

$3 – $9

Volume

0.1M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

8.0

Growth

5.8

Quality

C+

2.5

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$10.30

+249.15%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy3 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Revenue growth 346.90% QoQ

+ Debt/equity 0.42x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-13.13M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$3.08M	$4.35M	$4.52M	$10.02M	$10.02M
Net income	$-31.23M	$-43.21M	$-59.24M	$-90.05M	$-23.50M
EPS	—	—	—	—	$-2.77
Free cash flow	$-45.10M	$-55.74M	$-55.30M	$-68.30M	$-13.13M
Profit margin	-1,012.48%	-993.84%	-1,310.24%	-899.05%	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
NYXH	$130.99M	29	8.0	2.5	5.0	5.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Nyxoah trades at $2.95. Our Smart Value Score of 29/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. TTM revenue stands at $10.02M.

Frequently asked questions

What is Nyxoah's stock price?

Nyxoah (NYXH) trades at $2.95.

Is Nyxoah overvalued?

Smart Value Score 29/100 (Grade F, Strong Sell).

What is the price target of Nyxoah (NYXH)?

The analyst target price is $10.30, representing +249.2% upside from the current price of $2.95.

What is Nyxoah's revenue?

TTM revenue is $10.02M.

Piotroski F-Score?

2/9 — weak financial health.

Company info

SectorHEALTHCARE

IndustryMEDICAL INSTRUMENTS & SUPPLIES

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.nyxoah.com

Quick metrics

P/S ratio13.07x

ROE-110.90%

Beta0.87

50D MA$3.50

200D MA$5.04

Shares out0.04B

Float0.02B

Short ratio—

Avg volume0.1M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

NYXH vs LLY →NYXH vs JNJ →NYXH vs ABBV →Stock screener →